KAIROS PHARMA, LTD. Operating Cash Flow
KAIROS PHARMA, LTD. (KAPA) reported Operating Cash Flow of -$2.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- KAIROS PHARMA, LTD. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.01M.
- KAIROS PHARMA, LTD. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.04M.
- KAIROS PHARMA, LTD. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.08M.
- KAIROS PHARMA, LTD. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$838.00K.
- KAIROS PHARMA, LTD. net cash provided by (used in) operating activities for fiscal 2025 was -$3.44M.
- KAIROS PHARMA, LTD. net cash provided by (used in) operating activities for fiscal 2024 was -$3.96M, a 4982.72% decline from fiscal 2023.
- KAIROS PHARMA, LTD. net cash provided by (used in) operating activities for fiscal 2023 was $81.00K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.05M 10-Q · filed 2026-08-12 | -$3.13M derived: sum of 3 quarters · filed 2026-08-12 | -$3.97M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.04M 10-Q · filed 2026-05-13 | -$2.12M derived: sum of 2 quarters · filed 2026-05-13 | -$2.96M derived: sum of 3 quarters · filed 2026-05-13 | -$3.76M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.92M derived: sum of 2 quarters · filed 2026-03-31 | -$2.73M derived: sum of 3 quarters · filed 2026-08-12 | -$3.44M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$838.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.64M derived: sum of 2 quarters · filed 2026-08-12 | -$2.36M 10-Q · filed 2025-11-14 | -$4.16M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$805.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.52M 10-Q · filed 2026-08-12 | -$3.32M derived: sum of 3 quarters · filed 2026-08-12 | -$5.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$714.00K 10-Q · filed 2026-05-13 | -$2.52M derived: sum of 2 quarters · filed 2026-05-13 | -$4.54M derived: sum of 3 quarters · filed 2026-05-13 | -$4.71M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$3.82M derived: sum of 2 quarters · filed 2026-03-31 | -$3.99M derived: sum of 3 quarters · filed 2026-03-31 | -$3.96M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.19M derived: sum of 2 quarters · filed 2025-11-14 | -$2.15M 10-Q · filed 2025-11-14 | -$2.09M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$132.00K 10-Q · filed 2025-08-12 | -$66.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $36.00K 10-Q · filed 2025-05-14 | $102.00K derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $81.00K 10-K · filed 2025-04-15 | ||
| 2023-09-30 | $15.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |